Arca
Skip to content
Tools
Tools

Thromboembolism

Drug research and approvals for thromboembolism: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 159 studies of thromboembolism are recruiting on ClinicalTrials.gov, Health Canada has authorized 34 drug trials for it since 2013, FDA has 1 approved and 2 open orphan designations naming it, and the EU has 9 authorised medicines for it.

  • Recruiting worldwide: 159
  • Trials authorized in Canada: 34
  • FDA orphan approvals: 1
  • EU medicines: 9

Recruiting now

Newest posted first, of 159 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 2

  • WarfarinVitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
  • LepirudinThrombin inhibitor

Phase 3 10

Phase 2 3

Phase 1 or earlier 4

How its trials ended

912 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 220 whose ending is known, 51% met their primary endpoint, 8% missed it and 40% stopped early.

  • Completed, result not reported40244%
  • Ongoing17419%
  • Status unknown11613%
  • Met its primary endpoint11312%
  • Stopped: other or unclear435%
  • Stopped: enrollment or feasibility293%
  • Missed its primary endpoint182%
  • Stopped: sponsor or business decision81%
  • Stopped: lack of efficacy51%
  • Stopped: funding4<1%

Trials authorized in Canada

The 10 newest of 34; search them all in Canada trials
Aug 27, 2024The partum (postpartum aspirin to reduce thromboembolism undue morbidity) trialAcetylsalicylic acidGovernors of The University of CalgaryOngoing
Jul 29, 2024Tranexamic acid to decrease heavy menstrual bleeding in individuals anticoagulated for venous thromboembolism (t-rex hmb) pilot studyTranexamic acidUniversity Health NetworkPending
May 8, 2024A master protocol for a phase 2 randomized, double-blind, placebo-controlled study of REGN9933 and REGN7508, monoclonal antibodies against factor xi for…REGN9933 / REGN7508RegeneronClosed
May 3, 2024Reducing gastrointestinal bleeding with proton pump inhibitor therapy in acute venous thromboembolism: pilot randomized trial (radiant trial)OmeprazoleOttawa Hospital Research InstituteOngoing
Dec 2, 2022A phase 2, multicenter, randomized, open-label, active-control study of REGN9933, a factor xi monoclonal antibody, for prevention of venous thromboembolism…REGN9933RegeneronOngoing
Jan 7, 2022A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous pixaban on…AbelacimabAnthos Therapeutics, Inc.Ongoing
Oct 29, 2021Treatment of cvd with lose dose rivaroxaban in advanced CKD (TRACK)RivaroxabanThe George Institute for Global HealthClosed
Oct 21, 2021Primary thromboprophylaxis in patients with malignancy and central venous catheters: a randomized controlled trial (trim-line)RivaroxabanOttawa Hospital Research InstituteOngoing
Dec 3, 2020Towards improved adherence with extended vte prophylaxis after abdominal or pelvic major cancer surgeryApixabanHamilton Health Sciences CorporationClosed
Jul 28, 2020The saver trial: statins for venous event reduction in patients with venous thromboembolismRosuvastatinOttawa Hospital Research InstituteOngoing

FDA orphan designations

Approved first, then open designations, newest first
Dec 13, 1989ATnativFor the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when…Pharmacia & Upjohn ABApproved
Apr 8, 2024TecarfarinPrevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device (left ventricular assist…Cadrenal TherapeuticsDesignated
Mar 7, 2019TecarfarinPrevention of systemic thromboembolism of cardiac origin in patients with End Stage Renal Disease and atrial fibrillationCadrenal Therapeutics, Inc.Designated

Medicines authorised in the EU

Newest first
Nov 21, 2025Svariya (previously Rivaroxaban Koanaa)Rivaroxaban · genericPGF Pharma International d.o.o.EMA ↗
Feb 19, 2024Dabigatran etexilate Teva (previously Dabigatran etexilate Leon Farma)Dabigatran etexilate · genericTeva GmbHEMA ↗
May 26, 2023Dabigatran Etexilate AccordDabigatran etexilate · genericAccord Healthcare S.L.U.EMA ↗
Nov 12, 2021Rivaroxaban Viatris (previously Rivaroxaban Mylan)Rivaroxaban · genericViatris LimitedEMA ↗
May 19, 2021LydisilkaEstetrol; drospirenoneEstetra SPRLEMA ↗
Nov 16, 2020Rivaroxaban AccordRivaroxaban · genericAccord Healthcare S.L.U.EMA ↗
Jul 23, 2020Apixaban AccordApixaban · genericAccord Healthcare S.L.U.EMA ↗
Sep 15, 2016InhixaEnoxaparin sodium · biosimilarTechdow Pharma Netherlands B.V.EMA ↗
May 18, 2011EliquisApixabanBristol-Myers Squibb / Pfizer EEIGEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.